Hibiscus sabdariffa

View my plan →

The short answer

Tea or extracts may modestly lower blood pressure in people with elevated readings.

Evidence and scope: Conditional or population-specific
This status does not grade the ingredient for every goal, outcome, or person.
Important limitation: Benefit depends on the population, formulation, baseline status, and objective; results should not be generalized.
Before deciding: Key concern: Blood-pressure or diabetes medicines, pregnancy, liver concerns, and surgery require review.

01 / PRACTICAL GUIDE

Dose, absorption, and combinations

These are indication-specific reference or studied ranges—not a personalized prescription. Start with the objective, then check the form, label, medicines, and health conditions.

Reference range by objective

Blood pressureTea made from about 1.25–10 g/day calyces or product-equivalent in trials

Reference or studied range—not a personalized prescription. The product label or a clinician may specify a different dose.

Dose source ↗

More is not automatically better. A clinician or product label may specify a different amount.

Absorption / solubilityWater-soluble

Water-soluble or readily water-dispersible. This does not mean excess is always harmless.

How it is commonly taken

Prepare consistently; unsweetened tea avoids added sugar.

Do not combine casually

Blood-pressure or diabetes medicines, pregnancy, liver concerns, and surgery require review.

Dose and use source ↗

Dose and use links lead to primary or official source material. Search links are discovery tools, not proof that every returned paper applies.

02 / EVIDENCE

What the research says

We keep supportive, mixed, negative, safety, and contextual findings together. The headline never replaces the underlying papers.

1research papers in this ledger

13unique primary studies represented

1,205unique participants represented

These are audited counts for this JIVANA collection, not search-result totals. Participants are counted once when multiple papers use the same cohort; review papers are not added again to participant totals.

Open the research timelineResearch timeline

Entries are ordered by publication year. A study period appears only when the source reports it.

2022

Mixed or qualifiedPMID 34694241

Hibiscus sabdariffa for mild-to-moderate hypertension

Hibiscus lowered blood pressure versus placebo by about 6.7/4.4 mmHg in pooled analysis, but not in the metabolic-syndrome subgroup and not more than active treatments. Long-term efficacy and cardiovascular outcomes remain unknown.

Published: 2022n=1,205 participants13 primary studies represented

Study design and methods

Design: Systematic review and meta-analysis of 13 randomized trials
Population: 1,205 adults with mild-to-moderate hypertension or hypertension with metabolic syndrome
Intervention: Hibiscus preparations versus placebo, antihypertensive drugs, or other herbal products
Outcome: Systolic and diastolic blood pressure

Funding or conflict note: One author reported a paid consultation relevant to the study concept; the others reported no conflicts.

Open research record ↗

Unscreened discovery appendix—not evidence26 candidate publicationsSearch run: Aug 21, 2026

Complete for the displayed PubMed query at the search timestamp—not for all databases or every possible synonym. Candidates can be irrelevant, duplicate the same study, or report negative findings. They are never summed as evidence or participants until screened.

03 / SOURCES

Start with the source material

Official evidence overviewPubMed bounded human-evidence search Live PubMed discovery searchNational Library of Medicine

The live search is for discovery only. Search-result counts change and are not included in the audited totals above.

Recent PubMed discovery recordsDirect links to the first 12 records returned by the reproducible search. These are discovery candidates—not reviewed summaries or a count of supportive findings.

04 / EXPERT CONTEXT

Expert context—not evidence

Expert positions are dated context—not scientific evidence. They never raise the evidence status or become consensus by repetition.

No direct, source-verified endorsement is currently recorded. Research authorship or discussion alone is not treated as endorsement.